Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. Acquires 341,742 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. purchased 341,742 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. This represents a 3.67 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, March 7th, Ra Capital Management, L.P. purchased 110,206 shares of Janux Therapeutics stock. The shares were bought at an average price of $31.02 per share, with a total value of $3,418,590.12.

Janux Therapeutics Stock Down 0.4 %

Janux Therapeutics stock opened at $30.64 on Friday. Janux Therapeutics, Inc. has a 12 month low of $29.63 and a 12 month high of $71.71. The business has a 50 day moving average price of $41.74 and a two-hundred day moving average price of $47.55. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -26.19 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Plato Investment Management Ltd raised its holdings in shares of Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after buying an additional 187 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares in the last quarter. Rhumbline Advisers increased its holdings in Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock valued at $2,043,000 after purchasing an additional 599 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in Janux Therapeutics by 7.9% during the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company’s stock valued at $681,000 after purchasing an additional 928 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in Janux Therapeutics by 5.8% during the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company’s stock valued at $926,000 after purchasing an additional 949 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. BTIG Research increased their target price on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Scotiabank decreased their target price on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $88.00.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.